What question did this study set out to answer?

This study examines the impact of different BCR::ABL1 transcript types on treatment responses in CML patients.

December 8, 2025BloodOpen Access

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

View Full Paper

Ask AI

Bookmark

This study examines the impact of different BCR::ABL1 transcript types on treatment responses in CML patients.
Evaluated patients from the GIMEMA LabNet CML network
Analyzed BCR::ABL1 transcript types including e14a2 and e13a2
Compared responses between patients treated with imatinib and second-generation TKIs over 6, 12, and 24 months
Included a cohort of 9,699 patients with 1,471 meeting study criteria.
e14a2 carriers achieved superior molecular responses compared to e13a2 patients at multiple timepoints
2G-TKIs showed improved responses for e13a2 carriers compared to imatinib at earlier timepoints
Double isoform carriers demonstrated better outcomes compared to e13a2 in the first 12 months but similarities at 24 months.
Kinetic differences in molecular reduction based on transcript type were validated across treatments.

No takes yet. Share an insight, caveat, or question.

Analysis shows molecular response varies by transcript type in chronic myeloid leukemia patients receiving treatment.

Marsili et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark